Tag: Tryp Therapeutics - Page 3 - Psychedelic Alpha

Read more about the article Tryp Therapeutics Announces Q2 2021 Financial Results

Tryp Therapeutics Announces Q2 2021 Financial Results

Post published:April 29, 2021
Post category:Press Release

Read more about the article Tryp Therapeutics Reports on Key Milestones for 2021

Tryp Therapeutics Reports on Key Milestones for 2021

Post published:April 20, 2021
Post category:Press Release

Read more about the article Tryp Therapeutics Announces Listing on OTCQB and DTC Eligibility

Tryp Therapeutics Announces Listing on OTCQB and DTC Eligibility

Post published:April 5, 2021
Post category:Press Release

Read more about the article Tryp Therapeutics Announces Amendment to Option Plan and Option Grant

Tryp Therapeutics Announces Amendment to Option Plan and Option Grant

Post published:April 2, 2021
Post category:Press Release

Read more about the article Tryp Therapeutics Appoints Greg McKee as Chief Executive Officer

Tryp Therapeutics Appoints Greg McKee as Chief Executive Officer

Post published:April 1, 2021
Post category:Press Release

Read more about the article Tryp Therapeutics Announces Provisional Patent Filing For Improved Administration of Psychedelics

Tryp Therapeutics Announces Provisional Patent Filing For Improved Administration of Psychedelics

Post published:March 18, 2021
Post category:Press Release

Read more about the article Tryp Therapeutics Appoints Luke Hayes as Chief Financial Officer

Tryp Therapeutics Appoints Luke Hayes as Chief Financial Officer

Post published:March 9, 2021
Post category:Press Release

Read more about the article Tryp Therapeutics Announces Application to List on OTCQB

Tryp Therapeutics Announces Application to List on OTCQB

Post published:March 4, 2021
Post category:Press Release

Read more about the article Tryp Therapeutics to Present at the Stifel GMP Healthcare Conference

Tryp Therapeutics to Present at the Stifel GMP Healthcare Conference

Post published:February 24, 2021
Post category:Press Release

Read more about the article Tryp Therapeutics Completes $2 Million Strategic Financing

Tryp Therapeutics Completes $2 Million Strategic Financing

Post published:February 17, 2021
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.